NCT05357612View on ClinicalTrials.gov

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

PHASE4RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

August 31, 2026

Conditions
Neurodegenerative DiseasesParkinson DiseaseParkinson Disease Psychosis
Interventions
DRUG

Pimavanserin

PD related Psychosis

Trial Locations (1)

37212

RECRUITING

Vanderbilt University Medical Center, Nashville

Sponsors
All Listed Sponsors
collaborator

ACADIA Pharmaceuticals Inc.

INDUSTRY

lead

Vanderbilt University Medical Center

OTHER